We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

131 hedge funds and large institutions have $125M invested in ImmunityBio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 33

0.63% less ownership

Funds ownership: 8.95% → 8.32% (-0.63%)

5% less call options, than puts

Call options by funds: $1.99M | Put options by funds: $2.08M

12% less funds holding

Funds holding: 149 → 131 (-18)

37% less capital invested

Capital invested by funds: $200M → $125M (-$74.4M)

45% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 31

Holders
131
Holders Change
-18
Holders Change %
-12.08%
% of All Funds
2.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
54
Reduced
33
Closed
31
Calls
$1.99M
Puts
$2.08M
Net Calls
-$95K
Net Calls Change
+$1.83M

Top Buyers

1
BlackRock
BlackRock
New York
+$3.19M
2
Millennium Management
Millennium Management
New York
+$2.29M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.76M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.61M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.47M

Top Sellers

1
State Street
State Street
Massachusetts
-$19.6M
2
OIM
Oracle Investment Management
Connecticut
-$2.24M
3
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.99M
4
Marshall Wace
Marshall Wace
United Kingdom
-$861K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$764K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
101
Barclays
United Kingdom
$40K -$3.13K -778 -7%
SPC
102
Sigma Planning Corp
Michigan
$40K +$1.21K +300 +3%
SO
103
STRS Ohio
Ohio
$39K -$19.7K -4,900 -32%
CA
104
Claro Advisors
Massachusetts
$37K – – –
IUHSA
105
Itau Unibanco Holding S.A.
Brazil
$36K +$7.19K +1,791 +23%
Fidelity Investments
106
Fidelity Investments
Massachusetts
$33K -$403K -100,425 -92%
TRCT
107
Tower Research Capital (TRC)
New York
$22K -$133K -33,077 -85%
AIP
108
Ameritas Investment Partners
Nebraska
$19K – – –
CG
109
Cutler Group
California
$18K +$9.28K +2,310 +87%
S
110
SignatureFD
Georgia
$14K – – –
CAPTRUST Financial Advisors
111
CAPTRUST Financial Advisors
North Carolina
$7K – – –
National Bank of Canada
112
National Bank of Canada
Quebec, Canada
$7K – – –
ZIG
113
Zullo Investment Group
Pennsylvania
$7K – – –
MLICM
114
Metropolitan Life Insurance Company (MetLife)
New York
$6.86K -$11.3K -2,805 -60%
WOC
115
West Oak Capital
California
$6K – – –
WAM
116
Worth Asset Management
Texas
$6K – – –
Rockefeller Capital Management
117
Rockefeller Capital Management
New York
$5K – – –
Northwestern Mutual Wealth Management
118
Northwestern Mutual Wealth Management
Wisconsin
$4K +$241 +60 +6%
VRM
119
Vectors Research Management
New York
$4K +$4.02K +1,000 New
AF
120
Advisornet Financial
Minnesota
$3K – – –
AAP
121
Arax Advisory Partners
Colorado
$2K – – –
SWM
122
Spire Wealth Management
Virginia
$2K – – –
PA
123
PSI Advisors
Florida
$1K – – –
US Bancorp
124
US Bancorp
Minnesota
$1K – – –
ATC
125
Adirondack Trust Company
New York
$1K +$1.21K +300 New
3 4
5
6 7

IBRX Hedge Fund Activity: Q2 2022 in Review

131 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2022, worth a combined $125M — down 37% from $200M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of IBRX and 17 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 54 added.

The largest buyer was BlackRock, adding an estimated $3.19M. The largest seller was State Street, cutting an estimated $19.6M.

  • 131 institutional investors held ImmunityBio (IBRX) as of Q2 2022, down from 149 in Q1 2022.
  • Funds reported $125M of ImmunityBio stock for Q2 2022, down 37% quarter-over-quarter.
  • 17 funds opened new ImmunityBio positions in Q2 2022 and 31 closed out, a net change of -14 holders.
  • The largest ImmunityBio buyer in Q2 2022 was BlackRock, an estimated $3.19M added.
  • The largest ImmunityBio seller in Q2 2022 was State Street, an estimated $19.6M sold.

Based on aggregated 13F filings for Q2 2022.